Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EQL Pharma AB ( (SE:EQL) ) has issued an update.
EQL Pharma AB has called an extraordinary general meeting for 3 February 2026 at its Lund headquarters, inviting shareholders of record by 26 January to vote in person or by proxy in accordance with standard Swedish corporate governance procedures. The key item on the agenda is a proposed long-term incentive program for the Chief Sales Officer and Chief Financial Officer, comprising a directed issue of up to 220,000 warrants under the Warrants Program 2026/2030; by selectively granting warrants without applying shareholders’ preferential rights, the board aims to strengthen retention of key executives, align their interests more closely with shareholders and support the company’s long‑term development.
More about EQL Pharma AB
EQL Pharma AB is a Swedish pharmaceutical company based in Lund, focused on developing and commercialising generic medicines, with operations structured around prescription-based pharmaceutical products for the healthcare market.
Average Trading Volume: 33,786
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.66B
See more insights into EQL stock on TipRanks’ Stock Analysis page.